<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1142" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1142/" /><meta name="ncbi_pagename" content="Unverricht-Lundborg Disease - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Unverricht-Lundborg Disease - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Unverricht-Lundborg Disease" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2014/11/26" /><meta name="citation_author" content="Anna-Elina Lehesjoki" /><meta name="citation_author" content="Reetta Kälviäinen" /><meta name="citation_pmid" content="20301321" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1142/" /><meta name="citation_keywords" content="EPM1" /><meta name="citation_keywords" content="Progressive Myoclonus Epilepsy 1" /><meta name="citation_keywords" content="Unverricht-Lundborg Myoclonus Epilepsy" /><meta name="citation_keywords" content="Cystatin-B" /><meta name="citation_keywords" content="CSTB" /><meta name="citation_keywords" content="Unverricht-Lundborg Disease" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Unverricht-Lundborg Disease" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Anna-Elina Lehesjoki" /><meta name="DC.Contributor" content="Reetta Kälviäinen" /><meta name="DC.Date" content="2014/11/26" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1142/" /><meta name="description" content="Unverricht-Lundborg disease (EPM1) is a neurodegenerative disorder characterized by onset from age six to 15 years, stimulus-sensitive myoclonus, and tonic-clonic epileptic seizures. Some years after the onset, ataxia, incoordination, intentional tremor, and dysarthria develop. Individuals with EPM1 are mentally alert but show emotional lability, depression, and mild decline in intellectual performance over time." /><meta name="og:title" content="Unverricht-Lundborg Disease" /><meta name="og:type" content="book" /><meta name="og:description" content="Unverricht-Lundborg disease (EPM1) is a neurodegenerative disorder characterized by onset from age six to 15 years, stimulus-sensitive myoclonus, and tonic-clonic epileptic seizures. Some years after the onset, ataxia, incoordination, intentional tremor, and dysarthria develop. Individuals with EPM1 are mentally alert but show emotional lability, depression, and mild decline in intellectual performance over time." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1142/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/epm1/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1142/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B0013E040A0A10000000003450126.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1142_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1142_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/udd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ucd-overview/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1142_"><span class="title" itemprop="name">Unverricht-Lundborg Disease</span></h1><p class="contrib-group"><span itemprop="author">Anna-Elina Lehesjoki</span>, MD, PhD and <span itemprop="author">Reetta K&#x000e4;lvi&#x000e4;inen</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1142_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1142_ai__"><div class="contrib half_rhythm"><span itemprop="author">Anna-Elina Lehesjoki</span>, MD, PhD<div class="affiliation small">Folkhalsan Institute of Genetics and Neuroscience Center<br />University of Helsinki<br />Helsinki, Finland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="if.iknisleh@ikojsehel.anile-anna" class="oemail">if.iknisleh@ikojsehel.anile-anna</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Reetta K&#x000e4;lvi&#x000e4;inen</span>, MD, PhD<div class="affiliation small">Kuopio Epilepsy Center<br />Kuopio University Hospital<br />Kuopio, Finland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="if.huk@neniaivlak.atteer" class="oemail">if.huk@neniaivlak.atteer</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 24, 2004</span>; Last Update: <span itemprop="dateModified">November 26, 2014</span>.</p><p><em>Estimated reading time: 17 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="epm1.Summary" itemprop="description"><h2 id="_epm1_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Unverricht-Lundborg disease (EPM1) is a neurodegenerative disorder characterized by onset from age six to 15 years, stimulus-sensitive myoclonus, and tonic-clonic epileptic seizures. Some years after the onset, ataxia, incoordination, intentional tremor, and dysarthria develop. Individuals with EPM1 are mentally alert but show emotional lability, depression, and mild decline in intellectual performance over time.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>EPM1 results from defective function of cystatin B, a cysteine protease inhibitor, as a consequence of mutation of <i>CSTB</i>. The diagnosis can be confirmed by identifying the common dodecamer repeat expansion or other pathogenic variants in <i>CSTB</i>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Symptomatic pharmacologic and rehabilitative management, including psychosocial support, are the mainstay of care; valproic acid, the first drug of choice, diminishes myoclonus and the frequency of generalized seizures; clonazepam, approved by FDA for the treatment of myoclonic seizures, is an add-on therapy; high-dose piracetam is used to treat myoclonus; levetiracetam appears to be effective for both myoclonus and generalized seizures. Topiramate and zonisamide may also be used as add-on therapy.</p><p><i>Surveillance:</i> Lifelong clinical follow up, including evaluation of drug treatment and rehabilitation.</p><p><i>Agents/circumstances to avoid:</i> Phenytoin aggravates neurologic symptoms or even accelerates cerebellar degeneration; sodium channel blockers (carbamazepine, oxcarbazepine), GABAergic drugs (tiagabine, vigabatrin) and gabapentin and pregabalin may aggravate myoclonus and myoclonic seizures.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>EPM1 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if both <i>CSTB</i> pathogenic variants in a family are known.</p></div></div><div id="epm1.Diagnosis"><h2 id="_epm1_Diagnosis_">Diagnosis</h2><p>The diagnosis of Unverricht-Lundborg disease (EPM1) is suspected in a previously healthy child age six to 15 years who manifests the following:</p><ul><li class="half_rhythm"><div class="half_rhythm">Involuntary, action-activated myoclonic jerks AND/OR generalized tonic-clonic seizures</div></li><li class="half_rhythm"><div class="half_rhythm">Photosensitive, generalized spike-and-wave and polyspike-and-wave paroxysms on EEG</div><div class="half_rhythm">EEG is always abnormal, even before the onset of symptoms. The background activity is labile and may be slower than normal. Photosensitivity is marked.</div></li><li class="half_rhythm"><div class="half_rhythm">A gradual worsening of the neurologic symptoms (myoclonus and ataxia)</div></li><li class="half_rhythm"><div class="half_rhythm">Normal brain MRI</div></li></ul><p><b>Gene.</b>
<i>CSTB</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants are known to cause Unverricht-Lundborg disease [<a class="bk_pop" href="#epm1.REF.pennacchio.1998.251">Pennacchio et al 1998</a>]. Virtually all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have an unstable expansion of a 12-nucleotide (dodecamer) repeat 5'-CCC-CGC-CCC-GCG-3' (<a class="figpopup" href="/books/NBK1142/table/epm1.T.selected_cstb_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figepm1Tselectedcstbpathogenicvariants" rid-ob="figobepm1Tselectedcstbpathogenicvariants">g.513685_513696</a>) in the <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a> in at least one of the two altered <i>CSTB</i> alleles; the majority of individuals have two expanded repeats in the abnormal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> range.</p><p><b>Allele sizes</b></p><ul><li class="half_rhythm"><div><b>Normal alleles.</b> 2-3 dodecamer repeats</div></li><li class="half_rhythm"><div><b>Full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> alleles.</b> &#x02265;30 dodecamer repeats. The largest <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> observed to date using Southern blotting is approximately 125 dodecamer repeats (see <a class="figpopup" href="/books/NBK1142/table/epm1.T.selected_cstb_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figepm1Tselectedcstbpathogenicvariants" rid-ob="figobepm1Tselectedcstbpathogenicvariants">Table 2</a>).</div></li><li class="half_rhythm"><div><b>Alleles of questionable significance</b></div><ul><li class="half_rhythm"><div>Alleles of 12-17 dodecamer repeats <a class="figpopup" href="/books/NBK1142/table/epm1.T.selected_cstb_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figepm1Tselectedcstbpathogenicvariants" rid-ob="figobepm1Tselectedcstbpathogenicvariants">g.513685_513696(12_17)</a> have been observed, but individuals with alleles in this range have not undergone thorough clinical evaluation for signs and symptoms of EPM1.</div></li><li class="half_rhythm"><div>Alleles of 4-11 dodecamer repeats and 18-29 dodecamer repeats <a class="figpopup" href="/books/NBK1142/table/epm1.T.selected_cstb_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figepm1Tselectedcstbpathogenicvariants" rid-ob="figobepm1Tselectedcstbpathogenicvariants">g.513685_513696(18_29)</a> have not been reported.</div></li></ul></li></ul><div id="epm1.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Unverricht-Lundborg Disease</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1142/table/epm1.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epm1.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epm1.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_epm1.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_epm1.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_epm1.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>CSTB</i></td><td headers="hd_h_epm1.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for <a class="figpopup" href="/books/NBK1142/table/epm1.T.selected_cstb_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figepm1Tselectedcstbpathogenicvariants" rid-ob="figobepm1Tselectedcstbpathogenicvariants">g.513685_513696(30_125)</a>&#x000a0;<sup>2</sup></td><td headers="hd_h_epm1.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">99%&#x000a0;<sup>3</sup><br />~90%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_epm1.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>5,&#x000a0;6</sup></td><td headers="hd_h_epm1.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_epm1.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>7,&#x000a0;8</sup></td><td headers="hd_h_epm1.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="epm1.TF.1.1"><p class="no_margin">See <a href="/books/NBK1142/#epm1.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein. See <a href="#epm1.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>2. </dt><dd><div id="epm1.TF.1.2"><p class="no_margin">Alleles with dodecamer repeat expansion 30 to ~125</p></div></dd><dt>3. </dt><dd><div id="epm1.TF.1.3"><p class="no_margin">99% of disease alleles in Finnish individuals</p></div></dd><dt>4. </dt><dd><div id="epm1.TF.1.4"><p class="no_margin">90% of disease alleles worldwide</p></div></dd><dt>5. </dt><dd><div id="epm1.TF.1.5"><p class="no_margin">c.10G&#x0003e;C, c.67-1G&#x0003e;C, c.169-2A&#x0003e;G, c.202C&#x0003e;T, c.218_219delTC</p></div></dd><dt>6. </dt><dd><div id="epm1.TF.1.6"><p class="no_margin">Pathogenic variants included in a panel may vary by laboratory.</p></div></dd><dt>7. </dt><dd><div id="epm1.TF.1.7"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>8. </dt><dd><div id="epm1.TF.1.8"><p class="no_margin">Detects the five <i>CSTB</i> pathogenic variants noted in footnote 5 as well as novel variants.</p></div></dd></dl></div></div></div><div id="epm1.Testing_Strategy"><h3>Testing Strategy</h3><p><b>Confirming the diagnosis in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Targeted <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the dodecamer expansion of <i>CSTB</i> should be pursued first.</div></li><li class="half_rhythm"><div>When heterozygosity for the dodecamer expansion is found in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, it is appropriate to pursue <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for other <i>CSTB</i> pathogenic variants in the second <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> either by targeted analysis for a broader panel of pathogenic variants or by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</div></li></ul></div></div><div id="epm1.Clinical_Characteristics"><h2 id="_epm1_Clinical_Characteristics_">Clinical Characteristics</h2><div id="epm1.Clinical_Description"><h3>Clinical Description</h3><p>In more than half of individuals with Unverricht-Lundborg disease (EPM1), the first symptom is involuntary myoclonic jerks [<a class="bk_pop" href="#epm1.REF.k_lvi_inen.2008.549">K&#x000e4;lvi&#x000e4;inen et al 2008</a>]. The myoclonic jerks are action activated and stimulus sensitive, and may be provoked by light, physical exertion, and stress. They occur predominantly in the proximal muscles of the extremities and are asynchronous; they may be focal or multifocal and may generalize to a series of myoclonic seizures or even status myoclonicus (continuous myoclonic jerks involving a semi-loss of consciousness).</p><p>During the first five to ten years, the symptoms/myoclonic jerks characteristically progress and about one third of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals become severely incapacitated (wheelchair bound). Although the myoclonic jerks are disabling and resistant to therapy, the individual usually learns to tolerate them over time, provided that the psychosocial support is good and depression not too severe.</p><p>In almost half of individuals, the presenting symptom is tonic-clonic seizures. There may also be absence, psychomotor, and/or focal motor seizures. Epileptic seizures, infrequent in the early stages of the disease, often increase in frequency during the ensuing three to seven years. Later they may cease entirely with appropriate antiepileptic drug treatment. In rare cases, tonic-clonic seizures do not occur.</p><p>Neurologic findings initially seem normal; however, experienced observers usually note recurrent, almost imperceptible myoclonus, especially in response to photic stimuli or other stimuli (threat, clapping of hands, nose tapping, reflexes) or to action (movements made during neurologic examination) or to cognitive stimuli (task demanding cognitive and psychomotor processing). Some years after the onset, ataxia, incoordination, intentional tremor, and dysarthria develop.</p><p>Individuals with EPM1 have normal cognition but show emotional lability, depression, and mild decline in intellectual performance over time.</p><p>The disease course is inevitably progressive; however, the rate of deterioration especially in terms of walking capacity appears to vary even within the same family. Generalized tonic-clonic seizures are usually controlled with treatment, but myoclonic jerks may become severe, appear in series, and inhibit normal activities [<a class="bk_pop" href="#epm1.REF.magaudda.2006.860">Magaudda et al 2006</a>]. Myoclonic jerks may also be subcortical in origin and therefore difficult to control [<a class="bk_pop" href="#epm1.REF.danner.2009.81">Danner et al 2009</a>]. The individual becomes depressed and progression ensues. Education is often interrupted because of emotional, social, and intellectual problems.</p><p>In the past, life span was shortened; many individuals died eight to 15 years after the onset of disease, usually before age 30 years. With better pharmacologic, physiotherapeutic, and psychosocial supportive treatment, life expectancy appears to be near normal [<a class="bk_pop" href="#epm1.REF.k_lvi_inen.2008.549">K&#x000e4;lvi&#x000e4;inen et al 2008</a>].</p></div><div id="epm1.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Individuals with pathogenic variants in <i>CSTB</i> develop similar disease manifestations. There is preliminary evidence that correlation exists between the length of the expanded dodecamer repeat and the age of onset or disease severity [Author, personal communication]. However, disease severity also varies among <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals within a family with apparently similar repeat-size expansions. Moreover EPM1 resulting from <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> <i>CSTB</i> pathogenic variants (a dodecamer repeat expansion on one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and a single nucleotide variant or <a class="def" href="/books/n/gene/glossary/def-item/indel/">indel</a> variant on the other allele) presents with earlier age of onset, more severe myoclonus, and seizures that may be drug-resistant [<a class="bk_pop" href="#epm1.REF.koskenkorva.2011.515">Koskenkorva et al 2011</a>, <a class="bk_pop" href="#epm1.REF.canafoglia.2012.2120">Canafoglia et al 2012</a>]. The presence of variable phenotypes (even in siblings) suggests that interactions with other genetic factors influence the final disease presentation.</p></div><div id="epm1.Nomenclature"><h3>Nomenclature</h3><p>Unverricht-Lundborg disease was previously called Baltic myoclonus or Baltic myoclonic epilepsy. These names should no longer be used because the condition occurs worldwide.</p><p>An identical disorder, found in individuals from the Mediterranean countries and called Mediterranean myoclonus, is now known to be EPM1. The term progressive myoclonus epilepsy (PME) covers a large and varied group of diseases characterized by myoclonus, epilepsy, and progressive neurologic deterioration.</p></div><div id="epm1.Prevalence"><h3>Prevalence</h3><p>EPM1 is the major cause of progressive myoclonus epilepsy in North America; exact prevalence figures are not available.</p><p>EPM1 occurs worldwide, but its prevalence is increased in certain populations: in the North African countries of Tunisia, Algeria, and Morocco, where exact prevalence figures are not available; and in Finland, where its prevalence (1:25,000) is higher than anywhere else in the world. The incidence in Finland is estimated at 1:20,000 births.</p></div></div><div id="epm1.Genetically_Related_Allelic_Disorde"><h2 id="_epm1_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with mutation of <i>CSTB</i>.</p></div><div id="epm1.Differential_Diagnosis"><h2 id="_epm1_Differential_Diagnosis_">Differential Diagnosis</h2><p>At the onset of Unverricht-Lundborg disease (EPM1), juvenile myoclonic epilepsy (JME) &#x02013; which has a favorable outcome &#x02013;should be considered as a diagnostic alternative. Individuals with JME have a normal neurologic examination and the background of the EEG is undisturbed.</p><p>In case of progression, other forms of progressive myoclonus epilepsy, notably <a href="/books/n/gene/merrf/">myoclonic epilepsy with ragged red fibers</a> (MERRF), neuronal ceroid-lipofuscinoses, and <a href="/books/n/gene/lafora/">Lafora disease</a>, should be considered:</p><p>In individuals with an EPM1-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in whom a <i>CSTB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is not identified, the following four disorders should be considered.</p><ul><li class="half_rhythm"><div>An EPM1-like <a href="/books/n/gene/me-ataxia/">progressive myoclonus epilepsy-ataxia syndrome</a> has been shown to result from a <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PRICKLE1</i> [<a class="bk_pop" href="#epm1.REF.bassuk.2008.572">Bassuk et al 2008</a>]. Children present with ataxia at age four to five years and later develop a progressive myoclonus epilepsy <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> with mild or absent cognitive decline.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/amrf/">Action myoclonus &#x02013; renal failure syndrome</a> (myoclonus-renal failure, AMRF) is caused by pathogenic variants in <i>SCARB2</i> [<a class="bk_pop" href="#epm1.REF.berkovic.2008.673">Berkovic et al 2008</a>]. AMRF typically presents at ages 15 to 25 years either with neurologic symptoms (including tremor, action myoclonus, seizures, and ataxia) or with proteinuria that progresses to renal failure.</div></li><li class="half_rhythm"><div>Progressive myoclonus epilepsy-6 (EPM6) is caused by <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> pathogenic variants in <i>GOSR2</i> [<a class="bk_pop" href="#epm1.REF.corbett.2011.657">Corbett et al 2011</a>, <a class="bk_pop" href="#epm1.REF.boiss_lomax.2013.1146">Boiss&#x000e9; Lomax et al 2013</a>]. EPM6 presents with early-onset ataxia (average age 2 years), followed by action myoclonus and seizures later in childhood. Independent ambulation is lost in the second decade and <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop scoliosis by adolescence. Cognition is not usually affected.</div></li><li class="half_rhythm"><div>The disorder myoclonus epilepsy and ataxia due to pathogenic variants in the potassium channel (MEAK), caused by a recurrent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant in <i>KCNC1</i>, resembles EPM1 at disease onset [<a class="bk_pop" href="#epm1.REF.muona.2015.39">Muona et al 2015</a>]. MEAK presents between ages six and 15 years with myoclonus (sometimes reported as tremor). The later disease course is characterized by moderate to severe incapacitating myoclonus, infrequent tonic-clonic seizures, ataxia, and mild (if any) cognitive decline. The clinical course for MEAK is generally more severe than for EPM1.</div></li></ul><p>See <a href="http://omim.org/phenotypicSeries/PS254800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Epilepsy, progressive myoclonic: OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div><div id="epm1.Management"><h2 id="_epm1_Management_">Management</h2><div id="epm1.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with Unverricht-Lundborg disease (EPM1), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Clinical evaluation including walking, coordination, handwriting, school performance, and emotional features</div></li><li class="half_rhythm"><div>Examination of myoclonus including evaluation of myoclonus at rest, with action, and in response to stimuli</div></li><li class="half_rhythm"><div>EEG evaluation before initiation of therapy, as it is most characteristic before use of anticonvulsive medication</div></li><li class="half_rhythm"><div>Clinical genetics consultation</div></li></ul></div><div id="epm1.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Symptomatic pharmacologic and rehabilitative management are the mainstay of patient care [<a class="bk_pop" href="#epm1.REF.k_lvi_inen.2008.549">K&#x000e4;lvi&#x000e4;inen et al 2008</a>]:</p><ul><li class="half_rhythm"><div><b>Valproic acid</b> is the first drug of choice. It diminishes myoclonus and the frequency of generalized seizures.</div></li><li class="half_rhythm"><div><b>Clonazepam,</b> the only drug approved by the Food and Drug Administration (FDA) for the treatment of myoclonic seizures, is used as add-on therapy [<a class="bk_pop" href="#epm1.REF.shahwan.2005.239">Shahwan et al 2005</a>].</div></li><li class="half_rhythm"><div><b>High-dose piracetam</b> has been formally studied and has been found useful in the treatment of myoclonus [<a class="bk_pop" href="#epm1.REF.koskiniemi.1998.344">Koskiniemi et al 1998</a>].</div></li><li class="half_rhythm"><div><b>Levetiracetam</b> has been evaluated in several series and seems to be effective for both myoclonus and generalized seizures.</div></li><li class="half_rhythm"><div><b>Topiramate</b> and <b>zonisamide</b> may also be used as add-on therapies<b>.</b></div></li></ul></div><div id="epm1.Surveillance"><h3>Surveillance</h3><p>Patients need lifelong clinical follow up and psychosocial support including evaluation of the drug treatment and comprehensive rehabilitation.</p></div><div id="epm1.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>Phenytoin</b> should be avoided, as it has been found to have aggravating side effects on the associated neurologic symptoms, and may even accelerate cerebellar degeneration [<a class="bk_pop" href="#epm1.REF.eldridge.1983.838">Eldridge et al 1983</a>].</p><p><b>Sodium channel blockers</b> (carbamazepine, oxcarbazepine, phenytoin) and <b>GABAergic drugs</b> (tiagabine, vigabatrin) as well as <b>gabapentin</b> and <b>pregabalin</b> should in general be avoided as they may aggravate myoclonus and myoclonic seizures [<a class="bk_pop" href="#epm1.REF.medina.2005.307">Medina et al 2005</a>].</p></div><div id="epm1.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate the older and younger sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> in order to identify as early as possible those who would benefit from institution of treatment and preventive measures. If the pathogenic variants in the family are known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used to clarify the genetic status of at-risk sibs.</p><p>See <a href="#epm1.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="epm1.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Brivaracetam, a SV2A ligand that differs from levetiracetam by its mechanism of action profile, has demonstrated significant antiepileptic activity in experimental models of epilepsy and myoclonus. Brivaracetam has been granted orphan drug designation by the FDA (United States) for the treatment of symptomatic myoclonus, and by the EMEA (European Agency for the Evaluation of Medicinal Products; European Union) for the treatment of progressive myoclonic epilepsies.</p><p>Brivaracetam is currently being investigated as an add-on treatment for Unverricht-Lundborg disease in adolescents and adults.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div><div id="epm1.Other"><h3>Other</h3><p>Vagus nerve stimulator therapy reduces seizures and significantly improves cerebellar function on neurologic examination [<a class="bk_pop" href="#epm1.REF.smith.2000.1046">Smith et al 2000</a>].</p><p>N-acetylcysteine has been tried with variable results [<a class="bk_pop" href="#epm1.REF.edwards.2002.1447">Edwards et al 2002</a>].</p></div></div><div id="epm1.Genetic_Counseling"><h2 id="_epm1_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="epm1.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Unverricht-Lundborg disease (EPM1) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="epm1.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes and therefore carry one <i>CSTB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the risk of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>CSTB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Several individuals with Unverricht-Lundborg disease, both males and females, have produced children.</div></li><li class="half_rhythm"><div>The offspring of an individual with Unverricht-Lundborg disease are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CSTB</i>.</div></li><li class="half_rhythm"><div>Because of the low <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> in the general population, the risk that an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual would have children with a carrier is extremely low except in genetic isolates.</div></li></ul><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each sib of the proband's parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p></div><div id="epm1.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing is possible once the pathogenic variants have been identified in the family.</p><p>Carrier testing for the reproductive partners of a known <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> is possible.</p></div><div id="epm1.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#epm1.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>Testing of asymptomatic individuals younger than age 18 years.</b> Because practically all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have their first symptoms before age 18 years, requests from parents for testing of asymptomatic at-risk individuals younger than age 18 years may arise. Consensus holds that asymptomatic individuals younger than age 18 years who are at risk for adult-onset disorders for which no treatment exists is not considered appropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</p><p>In a family with an established diagnosis of EPM1, it is appropriate to consider testing of symptomatic individuals regardless of age.</p><p>For more information, see also the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</p><p><b>Testing of at-risk asymptomatic adult relatives of individuals with EPM1</b> is possible after <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has identified the specific pathogenic variants in the family. Such testing should be performed in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>. This testing is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals. Testing of asymptomatic at-risk individuals with nonspecific or equivocal symptoms is predictive testing, not diagnostic testing.</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="epm1.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once both <i>CSTB</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for EPM1 are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="epm1.Resources"><h2 id="_epm1_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition/unverricht-lundborg-disease" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Unverricht-Lundborg disease</a></div></li><li class="half_rhythm"><div><b>American Epilepsy Society (AES)</b></div><div><a href="http://www.aesnet.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.aesnet.org</a></div></li><li class="half_rhythm"><div><b>Epilepsy Foundation</b></div><div>8301 Professional Place East</div><div>Suite 200</div><div>Landover MD 20785-7223</div><div><b>Phone:</b> 800-332-1000 (toll-free)</div><div><b>Email:</b> ContactUs@efa.org</div><div><a href="https://www.epilepsy.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.epilepsy.com</a></div></li></ul></div><div id="epm1.Molecular_Genetics"><h2 id="_epm1_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="epm1.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Unverricht-Lundborg Disease: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1142/table/epm1.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epm1.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_epm1.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_epm1.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_epm1.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_epm1.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_epm1.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_epm1.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_epm1.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1476" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CSTB</i></a></td><td headers="hd_b_epm1.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1476" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">21q22<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_epm1.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P04080" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cystatin-B</a></td><td headers="hd_b_epm1.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/CSTB" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CSTB database</a></td><td headers="hd_b_epm1.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CSTB" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CSTB</a></td><td headers="hd_b_epm1.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CSTB[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CSTB</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="epm1.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="epm1.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Unverricht-Lundborg Disease (<a href="/omim/254800,601145" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1142/table/epm1.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epm1.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/254800" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">254800</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601145" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601145</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CYSTATIN B; CSTB</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>CSTB</i> consists of three exons, all of them coding, which span roughly 2.5 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Northern blot analysis shows a single transcript of approximately 0.8 kb. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1142/#epm1.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Fourteen different pathogenic variants have been identified [<a class="bk_pop" href="#epm1.REF.kagitanishimono.2002.55">Kagitani-Shimono et al 2002</a>, <a class="bk_pop" href="#epm1.REF.de_haan.2004.1061">de Haan et al 2004</a>, <a class="bk_pop" href="#epm1.REF.joensuu.2007.185">Joensuu et al 2007</a>, <a class="bk_pop" href="#epm1.REF.erdinc.2010.1">Erdinc et al 2010</a>, <a class="bk_pop" href="#epm1.REF.canafoglia.2012.2120">Canafoglia et al 2012</a>, <a class="bk_pop" href="#epm1.REF.pinto.2012.187">Pinto et al 2012</a>].</p><p>Among the more than 150 apparently unrelated families studied to date, all but one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual had at least one <i>CSTB</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> with an unstable expansion of a 12-nucleotide (dodecamer; 5'-CCC-CGC-CCC-GCG-3') repeat unit. The majority of affected individuals have this <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on both alleles. The expanded repeat is located 175 bp upstream from the translation initiation codon in the <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a> of <i>CSTB</i>. This pathogenic variant accounts for approximately 90% of Unverricht-Lundborg disease alleles found throughout the world, and 99% of affected Finnish individuals have two disease-causing dodecamer expansions.</p><p>Thirteen pathogenic variants occur in the transcription unit of <i>CSTB</i> (<a class="figpopup" href="/books/NBK1142/table/epm1.T.selected_cstb_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figepm1Tselectedcstbpathogenicvariants" rid-ob="figobepm1Tselectedcstbpathogenicvariants">Table 2</a>). The c.67-1G&#x0003e;C, c.202C&#x0003e;T, c.168+2_168+21delinsAA, and c.218_219delTC pathogenic variants have been observed in more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual; the remaining nine have been identified in one individual each. The c.10G&#x0003e;C and c.66G&#x0003e;A pathogenic variants are the only two pathogenic variants reported in <i>CSTB</i> that do not occur in a <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> form with the dodecamer repeat expansion.</p><div id="epm1.T.selected_cstb_pathogenic_variants" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>CSTB</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1142/table/epm1.T.selected_cstb_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epm1.T.selected_cstb_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">g.513685_513696(30_125) (dodecamer repeat in <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a>)</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NT_011515.11" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NT_011515<wbr style="display:inline-block"></wbr>​.11</a></td></tr><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.10G&#x0003e;C</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly4Arg</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_3" rowspan="13" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_000100.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000100<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/entrez/viewer.fcgi?val=NP_000091.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000091<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.66G&#x0003e;A</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.67-1G&#x0003e;C</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.125C&#x0003e;A</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser42Ter</td></tr><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.136C&#x0003e;T</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln46Ter</td></tr><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.149G&#x0003e;A</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly50Glu</td></tr><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.168G&#x0003e;A</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.=&#x000a0;<sup>1,&#x000a0;2</sup></td></tr><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.168+1_168+18del</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.168+2_168+21delinsAA</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.169-2A&#x0003e;G</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.202C&#x0003e;T</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg68Ter</td></tr><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.212A&#x0003e;C</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln71Pro</td></tr><tr><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.218_219delTC</td><td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu73ProfsTer3</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="epm1.TF.2.1"><p class="no_margin">p.(=) designates that protein has not been analyzed, but no change is expected</p></div></dd><dt>2. </dt><dd><div id="epm1.TF.2.2"><p class="no_margin">May produce abnormal <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> [<a class="bk_pop" href="#epm1.REF.kagitanishimono.2002.55">Kagitani-Shimono et al 2002</a>]</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Cystatin-B is an inhibitor of several papain-family cysteine proteases, cathepsins, which are lysosomal enzymes. Cystatin-B is a ubiquitously expressed 98-amino acid protein and has a molecular weight of 11 kd. Its physiologic function is unknown. Within cells, cystatin-B shows lysosomal, nuclear, and/or cytosolic localization [<a class="bk_pop" href="#epm1.REF.alakurtti.2005.208">Alakurtti et al 2005</a>]. CSTB has been reported to interact with histones and cathepsin L in the nucleus where it could regulate cathepsin L activity [<a class="bk_pop" href="#epm1.REF.ceru.2010.10078">Ceru et al 2010</a>].</p><p><i>Cstb</i>-deficient knockout mice display a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> similar to the human disease with progressive ataxia and myoclonic seizures [<a class="bk_pop" href="#epm1.REF.pennacchio.1998.251">Pennacchio et al 1998</a>]. The mice show neuronal apoptosis (especially of cerebellar granule cells), atrophy, and gliosis [<a class="bk_pop" href="#epm1.REF.pennacchio.1998.251">Pennacchio et al 1998</a>, <a class="bk_pop" href="#epm1.REF.shannon.2002.1085">Shannon et al 2002</a>]. Analysis of timing of pathologic changes in the brains of <i>Cstb</i>-deficient knockout mice have revealed early and localized microglial activation as the first pathologic hallmark, followed by activation of astroglia in brain regions where neuron loss subsequently occurs [<a class="bk_pop" href="#epm1.REF.tegelberg.2012.40">Tegelberg et al 2012</a>]. These changes are most pronounced in the thalamocortical system. Microglial activation is accompanied by the presence of inflammatory markers and peripheral immune cells in the brains of <i>Cstb</i>-deficient mice, implying the contribution of neuroinflammation to disease pathogenesis [<a class="bk_pop" href="#epm1.REF.okuneva.2015.400">Okuneva et al 2015</a>].</p><p>Impaired redox homeostasis has been reported as a pathophysiologic mechanism in EPM1 whereby dysregulation of cystatin-B-cathepsin B signaling may serve as a critical mechanism coupling oxidative stress to neuronal degeneration and death [<a class="bk_pop" href="#epm1.REF.lehtinen.2009.5910">Lehtinen et al 2009</a>]. Cystatin-B knockout or knockdown sensitizes cerebellar granule neurons to oxidative stress-induced cell death, mediated by cathepsin B. Moreover, the cerebella of <i>Cstb</i>-deficient knockout mice show evidence of oxidative damage in vivo, reflected by depletion of antioxidants and increased lipid peroxidation [<a class="bk_pop" href="#epm1.REF.lehtinen.2009.5910">Lehtinen et al 2009</a>].</p><p>There is growing evidence from studies in <i>Cstb</i>-deficient knockout mice for the role of altered GABAergic signaling with subsequent loss of GABA inhibition as a mechanism underlying the latent hyperexcitability resulting in myoclonus and seizures [<a class="bk_pop" href="#epm1.REF.franceschetti.2007.675">Franceschetti et al 2007</a>, <a class="bk_pop" href="#epm1.REF.buzzi.2012.216">Buzzi et al 2012</a>, <a class="bk_pop" href="#epm1.REF.joensuu.2014.e89321">Joensuu et al 2014</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The major <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> underlying Unverricht-Lundborg disease, the dodecamer repeat g.513685_513696(30_125), results in a significantly reduced amount of <i>CSTB</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>: 5%-10% of the expression found in controls [<a class="bk_pop" href="#epm1.REF.joensuu.2007.185">Joensuu et al 2007</a>]. Consequently, cells of individuals with Unverricht-Lundborg disease display significantly reduced CSTB protein expression [<a class="bk_pop" href="#epm1.REF.alakurtti.2005.208">Alakurtti et al 2005</a>, <a class="bk_pop" href="#epm1.REF.joensuu.2007.185">Joensuu et al 2007</a>] and reduced CSTB inhibitory activity [<a class="bk_pop" href="#epm1.REF.rinne.2002.380">Rinne et al 2002</a>]. Cathepsin activity is significantly increased [<a class="bk_pop" href="#epm1.REF.rinne.2002.380">Rinne et al 2002</a>].</p><ul><li class="half_rhythm"><div>The c.66G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> affects the last nucleotide of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1 and it has experimentally verified to alter <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>.</div></li><li class="half_rhythm"><div>The c.67-1G&#x0003e;C, c.168+1_168+18del, and c.169-2A&#x0003e;G pathogenic variants affect splice sites and predict <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> defects.</div></li><li class="half_rhythm"><div>The c.67-1G&#x0003e;C <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> results in skipping of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2 and predicts an <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of 34 amino acids.</div></li><li class="half_rhythm"><div>The c.67-1G&#x0003e;C mutated mRNAs appear to be unstable.</div></li><li class="half_rhythm"><div>The c.168+1_168+18del <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> also results in aberrant <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of <i>CSTB</i> with two different transcripts, but the consequence of the c.169-2A&#x0003e;G pathogenic variant as a putative <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variant has not been experimentally tested.</div></li><li class="half_rhythm"><div>The c.168+2_168+21delinsAA <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is a complex <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> that involves the donor <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> of <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 2 and is predicted to lead to an aberrant transcript.</div></li><li class="half_rhythm"><div>The c.168G&#x0003e;A affects the last nucleotide of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2 and its consequence as a putative <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variant has not been experimentally tested.</div></li><li class="half_rhythm"><div>Pathogenic variants c.125C&#x0003e;A, c.136C&#x0003e;T, c.202C&#x0003e;T, and c.218_219delTC predict truncated proteins of 42, 46, 68, and 74 amino acids, respectively.</div></li><li class="half_rhythm"><div>The c.202C&#x0003e;T (p.Arg68Ter) mutated transcript and protein are unstable [<a class="bk_pop" href="#epm1.REF.alakurtti.2005.208">Alakurtti et al 2005</a>, <a class="bk_pop" href="#epm1.REF.joensuu.2007.185">Joensuu et al 2007</a>], implying reduced CSTB expression as the primary pathophysiologic mechanism.</div></li></ul><p>All three of the following <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> mutated proteins fail to associate with lysosomes, implying the physiologic importance of CSTB-lysosome association [<a class="bk_pop" href="#epm1.REF.alakurtti.2005.208">Alakurtti et al 2005</a>, <a class="bk_pop" href="#epm1.REF.joensuu.2007.185">Joensuu et al 2007</a>]:</p><ul><li class="half_rhythm"><div>The c.10G&#x0003e;C <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> results in the substitution of a highly conserved glycine to an arginine at amino acid position 4 (p.Gly4Arg), critical for cathepsin binding.</div></li><li class="half_rhythm"><div>The c.149G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> results in the substitution of glycine to glutamic acid (p.Gly50Glu) [<a class="bk_pop" href="#epm1.REF.joensuu.2007.185">Joensuu et al 2007</a>]. It affects the highly conserved QVVAG-motif in the first beta-hairpin loop important for the complex formation with cathepsins.</div></li><li class="half_rhythm"><div>The c.212A&#x0003e;C <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> results in the substitution of a glutamine at position 71 by a proline (p.Gln71Pro) [<a class="bk_pop" href="#epm1.REF.de_haan.2004.1061">de Haan et al 2004</a>]. The glutamine does not interact directly with target proteases, but is located proximal to the second hairpin loop, which also contributes to protease binding.</div></li></ul></div><div id="epm1.References"><h2 id="_epm1_References_">References</h2><div id="epm1.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.alakurtti.2005.208">Alakurtti K, Weber E, Rinne R, Theil G, de Haan GJ, Lindhout D, Salmikangas P, Saukko P, Lahtinen U, Lehesjoki AE. Loss of lysosomal association of cystatin B proteins representing progressive myoclonus epilepsy, EPM1, mutations. <span><span class="ref-journal">Eur J Hum Genet. </span>2005;<span class="ref-vol">13</span>:208–15.</span> [<a href="/pubmed/15483648" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15483648</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.bassuk.2008.572">Bassuk AG, Wallace RH, Buhr A, Buller AR, Afawi Z, Shimojo M, Miyata S, Chen S, Gonzalez-Alegre P, Griesbach HL, Wu S, Nashelsky M, Vladar EK, Antic D, Ferguson PJ, Cirak S, Voit T, Scott MP, Axelrod JD, Gurnett C, Daoud AS, Kivity S, Neufeld MY, Mazarib A, Straussberg R, Walid S, Korczyn AD, Slusarski DC, Berkovic SF, El-Shanti HI. A homozygous mutation in human PRICKLE1 causes an autosomal-recessive progressive myoclonus epilepsy-ataxia syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>2008;<span class="ref-vol">83</span>:572–81.</span> [<a href="/pmc/articles/PMC2668041/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2668041</span></a>] [<a href="/pubmed/18976727" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18976727</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.berkovic.2008.673">Berkovic SF, Dibbens LM, Oshlack A, Silver JD, Katerelos M, Vears DF, L&#x000fc;llmann-Rauch R, Blanz J, Zhang KW, Stankovich J, Kalnins RM, Dowling JP, Andermann E, Andermann F, Faldini E, D'Hooge R, Vadlamudi L, Macdonell RA, Hodgson BL, Bayly MA, Savige J, Mulley JC, Smyth GK, Power DA, Saftig P, Bahlo M. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. <span><span class="ref-journal">Am J Hum Genet. </span>2008;<span class="ref-vol">82</span>:673–84.</span> [<a href="/pmc/articles/PMC2427287/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2427287</span></a>] [<a href="/pubmed/18308289" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18308289</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.boiss_lomax.2013.1146">Boiss&#x000e9; Lomax L, Bayly MA, Hjalgrim H, M&#x000f8;ller RS, Vlaar AM, Aaberg KM, Marquardt I, Gandolfo LC, Willemsen M, Kamsteeg EJ, O'Sullivan JD, Korenke GC, Bloem BR, de Coo IF, Verhagen JM, Said I, Prescott T, Stray-Pedersen A, Rasmussen M, Vears DF, Lehesjoki AE, Corbett MA, Bahlo M, Gecz J, Dibbens LM, Berkovic SF. "North Sea" progressive myoclonus epilepsy: phenotype of subjects with GOSR2 mutation. <span><span class="ref-journal">Brain. </span>2013;<span class="ref-vol">136</span>:1146–54.</span> [<a href="/pubmed/23449775" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23449775</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.buzzi.2012.216">Buzzi A, Chikhladze M, Falcicchia C, Paradiso B, Lanza G, Soukupova M, Marti M, Morari M, Franceschetti S, Simonato M. Loss of cortical GABA terminals in Unverricht-Lundborg disease. <span><span class="ref-journal">Neurobiol Dis. </span>2012;<span class="ref-vol">47</span>:216–24.</span> [<a href="/pubmed/22538221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22538221</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.canafoglia.2012.2120">Canafoglia L, Gennaro E, Capovilla G, Gobbi G, Boni A, Beccaria F, Viri M, Michelucci R, Agazzi P, Assereto S, Coviello DA, Di Stefano M, Rossi Sebastiano D, Franceschetti S, Zara F. Electroclinical presentation and genotype-phenotype relationships in patients with Unverricht-Lundborg disease carrying compound heterozygous CSTB point and indel mutations. <span><span class="ref-journal">Epilepsia. </span>2012;<span class="ref-vol">53</span>:2120–7.</span> [<a href="/pubmed/23205931" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23205931</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.ceru.2010.10078">Ceru S, Konjar S, Maher K, Repnik U, Krizaj I, Bencina M, Renko M, Nepveu A, Zerovnik E, Turk B, Kopitar-Jerala N. Stefin B interacts with histones and cathepsin L in the nucleus. <span><span class="ref-journal">J Biol Chem. </span>2010;<span class="ref-vol">285</span>:10078–86.</span> [<a href="/pmc/articles/PMC2843170/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2843170</span></a>] [<a href="/pubmed/20075068" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20075068</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.corbett.2011.657">Corbett MA, Schwake M, Bahlo M, Dibbens LM, Lin M, Gandolfo LC, Vears DF, O'Sullivan JD, Robertson T, Bayly MA, Gardner AE, Vlaar AM, Korenke GC, Bloem BR, de Coo IF, Verhagen JM, Lehesjoki AE, Gecz J, Berkovic SF. A mutation in the Golgi Qb-SNARE gene GOSR2 causes progressive myoclonus epilepsy with early ataxia. <span><span class="ref-journal">Am J Hum Genet. </span>2011;<span class="ref-vol">88</span>:657–63.</span> [<a href="/pmc/articles/PMC3146720/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3146720</span></a>] [<a href="/pubmed/21549339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21549339</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.danner.2009.81">Danner N, Julkunen P, Khyuppenen J, Hukkanen T, K&#x000f6;n&#x000f6;nen M, S&#x000e4;is&#x000e4;nen L, Koskenkorva P, Vanninen R, Lehesjoki AE, K&#x000e4;lvi&#x000e4;inen R, Mervaala E. Altered cortical inhibition in Unverricht-Lundborg type progressive myoclonus epilepsy (EPM1). <span><span class="ref-journal">Epilepsy Res. </span>2009;<span class="ref-vol">85</span>:81–8.</span> [<a href="/pubmed/19321308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19321308</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.de_haan.2004.1061">de Haan GJ, Halley DJ, Doelman JC, Geesink HH, Augustijn PB, Jager-Jongkind AD, Majoie M, Bader AJ, Leliefeld-Ten Doeschate LA, Deelen WH, Bertram E, Lehesjoki AE, Lindhout D. Univerricht-Lundborg disease: underdiagnosed in the Netherlands. <span><span class="ref-journal">Epilepsia. </span>2004;<span class="ref-vol">45</span>:1061–3.</span> [<a href="/pubmed/15329070" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15329070</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.edwards.2002.1447">Edwards MJ, Hargreaves IP, Heales SJ, Jones SJ, Ramachandran V, Bhatia KP, Sisodiya S. N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">59</span>:1447–9.</span> [<a href="/pubmed/12427904" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12427904</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.eldridge.1983.838">Eldridge R, Iivanainen M, Stern R, Koerber T, Wilder BJ. "Baltic" myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. <span><span class="ref-journal">Lancet. </span>1983;<span class="ref-vol">2</span>:838–42.</span> [<a href="/pubmed/6137660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6137660</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.erdinc.2010.1">Erdinc OO, Joensuu T, Ilgen-Uslu F, Bebek N, &#x000d6;zkara C, Tutkavul K, G&#x000fc;nd&#x000fc;z A, Lehesjoki AE, Baykan B. Unverricht-Lundborg Disease in Turkey: Delineating the phenotype between cystatin B mutation positive and negative cases. <span><span class="ref-journal">J Neurol Sci (Turk). </span>2010;<span class="ref-vol">27</span>:1–11.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.franceschetti.2007.675">Franceschetti S, Sancini G, Buzzi A, Zucchini S, Paradiso B, Magnaghi G, Frassoni C, Chikhladze M, Avanzini G, Simonato M. A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression. <span><span class="ref-journal">Neurobiol Dis. </span>2007;<span class="ref-vol">25</span>:675–85.</span> [<a href="/pubmed/17188503" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17188503</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.joensuu.2007.185">Joensuu T, Kuronen M, Alakurtti K, Tegelberg S, Hakala P, Aalto A, Huopaniemi L, Aula N, Michellucci R, Eriksson K, Lehesjoki AE. Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients. <span><span class="ref-journal">Eur J Hum Genet. </span>2007;<span class="ref-vol">15</span>:185–93.</span> [<a href="/pubmed/17003839" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17003839</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.joensuu.2014.e89321">Joensuu T, Tegelberg S, Reinmaa E, Segerstr&#x000e5;le M, Hakala P, Pehkonen H, Korpi ER, Tyynel&#x000e4; J, Taira T, Hovatta I, Kopra O, Lehesjoki AE. Gene expression alterations in the cerebellum and granule neurons of Cstb(-/-) mouse are associated with early synaptic changes and inflammation. <span><span class="ref-journal">PLoS One. </span>2014;<span class="ref-vol">9</span>:e89321.</span> [<a href="/pmc/articles/PMC3937333/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3937333</span></a>] [<a href="/pubmed/24586687" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24586687</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.kagitanishimono.2002.55">Kagitani-Shimono K, Imai K, Okamoto N, Ono J, Okada S. Unverricht-Lundborg disease with cystatin B gene abnormalities. <span><span class="ref-journal">Pediatr Neurol. </span>2002;<span class="ref-vol">26</span>:55–60.</span> [<a href="/pubmed/11814737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11814737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.k_lvi_inen.2008.549">K&#x000e4;lvi&#x000e4;inen R, Khyuppenen J, Koskenkorva P, Eriksson K, Vanninen R, Mervaala E. Clinical picture of EPM1-Unverricht-Lundborg disease. <span><span class="ref-journal">Epilepsia. </span>2008;<span class="ref-vol">49</span>:549–56.</span> [<a href="/pubmed/18325013" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18325013</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.koskenkorva.2011.515">Koskenkorva P, Hypp&#x000f6;nen J, Aiki&#x000e4; M, Mervaala E, Kiviranta T, Eriksson K, Lehesjoki AE, Vanninen R, K&#x000e4;lvi&#x000e4;inen R. Severer phenotype in Unverricht-Lundborg disease (EPM1) patients compound heterozygous for the dodecamer repeat expansion and the c.202C&#x0003e;T mutation in the CSTB gene. <span><span class="ref-journal">Neurodegener Dis. </span>2011;<span class="ref-vol">8</span>:515–22.</span> [<a href="/pubmed/21757863" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21757863</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.koskiniemi.1998.344">Koskiniemi M, Van Vleymen B, Hakamies L, Lamusuo S, Taalas J. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1998;<span class="ref-vol">64</span>:344–8.</span> [<a href="/pmc/articles/PMC2169975/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2169975</span></a>] [<a href="/pubmed/9527146" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9527146</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.lehtinen.2009.5910">Lehtinen MK, Tegelberg S, Schipper H, Su H, Zukor H, Manninen O, Kopra O, Joensuu T, Hakala P, Bonni A, Lehesjoki A-E. Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1. <span><span class="ref-journal">J Neurosci. </span>2009;<span class="ref-vol">29</span>:5910–5.</span> [<a href="/pmc/articles/PMC2694495/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2694495</span></a>] [<a href="/pubmed/19420257" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19420257</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.magaudda.2006.860">Magaudda A, Ferlazzo E, Nguyen VH, Genton P. Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients. <span><span class="ref-journal">Epilepsia. </span>2006;<span class="ref-vol">47</span>:860–6.</span> [<a href="/pubmed/16686650" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16686650</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.medina.2005.307">Medina MT, Martinez-Juarez IE, Duron RM, Genton P, Guerrini R, Dravet C, Bureau M, Perez-Gosiengfiao KT, Amador C, Bailey JN, Chaves-Sell F, Delgado-Escueta AV. Treatment of myoclonic epilepsies of childhood, adolescence, and adulthood. <span><span class="ref-journal">Adv Neurol. </span>2005;<span class="ref-vol">95</span>:307–23.</span> [<a href="/pubmed/15508934" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15508934</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.muona.2015.39">Muona M, Berkovic SF, Dibbens LM, Oliver KL, Maljevic S, Bayly MA, Joensuu T, Canafoglia L, Franceschetti S, Michelucci R, Markkinen S, Heron SE, Hildebrand MS, Andermann E, Andermann F, Gambardella A, Tinuper P, Licchetta L, Scheffer IE, Criscuolo C, Filla A, Ferlazzo E, Ahmad J, Ahmad A, Baykan B, Said E, Topcu M, Riguzzi P, King MD, Ozkara C, Andrade DM, Engelsen BA, Crespel A, Lindenau M, Lohmann E, Saletti V, Massano J, Privitera M, Espay AJ, Kauffmann B, Duchowny M, M&#x000f8;ller RS, Straussberg R, Afawi Z, Ben-Zeev B, Samocha KE, Daly MJ, Petrou S, Lerche H, Palotie A, Lehesjoki AE. A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy. <span><span class="ref-journal">Nat Genet. </span>2015;<span class="ref-vol">47</span>:39–46.</span> [<a href="/pmc/articles/PMC4281260/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4281260</span></a>] [<a href="/pubmed/25401298" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25401298</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.okuneva.2015.400">Okuneva O, K&#x000f6;rber I, Li Z, Tian L, Joensuu T, Kopra O, Lehesjoki AE. Abnormal microglial activation in the Cstb(-/-) mouse, a model for progressive myoclonus epilepsy, EPM1. <span><span class="ref-journal">Glia. </span>2015;<span class="ref-vol">63</span>:400–11.</span> [<a href="/pubmed/25327891" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25327891</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.pennacchio.1998.251">Pennacchio LA, Bouley DM, Higgins KM, Scott MP, Noebels JL, Myers RM. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. <span><span class="ref-journal">Nat Genet. </span>1998;<span class="ref-vol">20</span>:251–8.</span> [<a href="/pubmed/9806543" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9806543</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.pinto.2012.187">Pinto E, Freitas J, Duarte AJ, Ribeiro I, Ribeiro D, Lima JL, Chaves J, Amaral O. Unverricht-Lundborg disease: homozygosity for a new splicing mutation in the cystatin B gene. <span><span class="ref-journal">Epilepsy Res. </span>2012;<span class="ref-vol">99</span>:187–90.</span> [<a href="/pubmed/22154554" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22154554</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.rinne.2002.380">Rinne R, Saukko P, Jarvinen M, Lehesjoki AE. Reduced cystatin B activity correlates with enhanced cathepsin activity in progressive myoclonus epilepsy. <span><span class="ref-journal">Ann Med. </span>2002;<span class="ref-vol">34</span>:380–5.</span> [<a href="/pubmed/12452481" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12452481</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.shahwan.2005.239">Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. <span><span class="ref-journal">Lancet Neurol. </span>2005;<span class="ref-vol">4</span>:239–48.</span> [<a href="/pubmed/15778103" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15778103</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.shannon.2002.1085">Shannon P, Pennacchio LA, Houseweart MK, Minassian BA, Myers RM. Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2002;<span class="ref-vol">61</span>:1085–91.</span> [<a href="/pubmed/12484571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12484571</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.smith.2000.1046">Smith B, Shatz R, Elisevich K, Bespalova IN, Burmeister M. Effects of vagus nerve stimulation on progressive myoclonus epilepsy of Unverricht-Lundborg type. <span><span class="ref-journal">Epilepsia. </span>2000;<span class="ref-vol">41</span>:1046–8.</span> [<a href="/pubmed/10961635" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10961635</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epm1.REF.tegelberg.2012.40">Tegelberg S, Kopra O, Joensuu T, Cooper JD, Lehesjoki AE. Early microglial activation precedes neuronal loss in the brain of the Cstb-/- mouse model of progressive myoclonus epilepsy, EPM1. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2012;<span class="ref-vol">71</span>:40–53.</span> [<a href="/pubmed/22157618" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22157618</span></a>]</div></li></ul></div></div><div id="epm1.Chapter_Notes"><h2 id="_epm1_Chapter_Notes_">Chapter Notes</h2><div id="epm1.Author_History"><h3>Author History</h3><p>Reetta K&#x000e4;lvi&#x000e4;inen, MD, PhD (2007-present) <br />Marja-Leena Koskiniemi, MD, PhD; University of Helsinki (2004-2007) <br />Anna-Elina Lehesjoki, MD, PhD (2004-present)</p></div><div id="epm1.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>26 November 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>18 June 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>18 September 2007 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> available on a clinical basis</div></li><li class="half_rhythm"><div>12 February 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>24 June 2004 (me) Review posted live</div></li><li class="half_rhythm"><div>6 February 2004 (ael) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1142</span><span class="label">PMID: <a href="/pubmed/20301321" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301321</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/udd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ucd-overview/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1142&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1142/?report=reader">PubReader</a></li><li><a href="/books/NBK1142/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1142" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1142" style="display:none" title="Cite this Page"><div class="bk_tt">Lehesjoki AE, Kälviäinen R. Unverricht-Lundborg Disease. 2004 Jun 24 [Updated 2014 Nov 26]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1142/pdf/Bookshelf_NBK1142.pdf">PDF version of this page</a> (422K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#epm1.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#epm1.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#epm1.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#epm1.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#epm1.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#epm1.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#epm1.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#epm1.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#epm1.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#epm1.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#epm1.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1476[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CSTB</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1486550" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1486550" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1486550" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1486550" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18325013" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Clinical picture of EPM1-Unverricht-Lundborg disease.</a><span class="source">[Epilepsia. 2008]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Clinical picture of EPM1-Unverricht-Lundborg disease.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kälviäinen R, Khyuppenen J, Koskenkorva P, Eriksson K, Vanninen R, Mervaala E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Epilepsia. 2008 Apr; 49(4):549-56. Epub 2008 Mar 5.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19087113" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.</a><span class="source">[Epilepsia. 2008]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Delgado-Escueta AV, Bourgeois BF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Epilepsia. 2008 Dec; 49 Suppl 9:13-24. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301774" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PRICKLE1</i>-Related Progressive Myoclonus Epilepsy with Ataxia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PRICKLE1</i>-Related Progressive Myoclonus Epilepsy with Ataxia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fox MH, Bassuk AG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301563" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Progressive Myoclonus Epilepsy, Lafora Type</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Progressive Myoclonus Epilepsy, Lafora Type<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Jansen AC, Andermann E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28377970" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Impaired osteoclast homeostasis in the cystatin B-deficient mouse model of progressive myoclonus epilepsy.</a><span class="source">[Bone Rep. 2015]</span><div class="brieflinkpop offscreen_noflow">Impaired osteoclast homeostasis in the cystatin B-deficient mouse model of progressive myoclonus epilepsy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Manninen O, Puolakkainen T, Lehto J, Harittu E, Kallonen A, Peura M, Laitala-Leinonen T, Kopra O, Kiviranta R, Lehesjoki AE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Bone Rep. 2015 Dec; 3:76-82. Epub 2015 Nov 6.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301321" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301321" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0411ec75f66d18aaeb1c4b">Unverricht-Lundborg Disease - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Unverricht-Lundborg Disease - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:50:36-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8B0013E040A0A10000000003450126&amp;ncbi_session=CE8B0013E0411EB1_0837SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1142%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1142&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1142/&amp;ncbi_pagename=Unverricht-Lundborg Disease - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B0013E0411EB1_0837SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>